Cilostazol was associated with a trend toward reduction of in-stent restenosis in patients with carotid artery stenting at 2 years, according to findings presented at the International Stroke Conference.
However, compared with other antiplatelet agents, cilostazol did not affect CV events, mortality or bleeding, researchers from the CAS-CARE study reported.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2020 Healio All Rights Reserved.